Monoclonal antibody HNK20

Drug Profile

Monoclonal antibody HNK20

Alternative Names: Anti-RSV monoclonal antibody HNK20; HNK 20; MAb HNK20; Monoclonal IgA antibody HNK20

Latest Information Update: 23 Apr 2003

Price : $50

At a glance

  • Originator Acambis
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 11 Dec 2000 OraVax is now called Acambis
  • 24 May 1999 OraVax acquired by Peptide Therapeutics
  • 20 Jun 1997 Data have been added to the therapeutic trials and adverse event sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top